alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.2020 Medical image communications device. ( a ) *Identification.* A medical image communications device provides electronic transfer of medical image data between medical devices. It may include a physical communications medium, modems, and interfaces. It may provide simple image review software functionality for medical image processing and manipulation, such as grayscale window and level, zoom and pan, user delineated geometric measurements, compression, or user added image annotations. The device does not perform advanced image processing or complex quantitative functions. This does not include electronic transfer of medical image software functions.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 892.9.
[63 FR 23387, Apr. 29, 1998; 63 FR 44998, Aug. 24, 1998, as amended at 65 FR 2323, Jan. 14, 2000, 86 FR 20283, Apr. 19, 2021]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     WINSTON RESOURCES, INC. AND SUBSIDIARIES

             FINANCIAL DATA SCHEDULES
       FOR THE SIX MONTHS ENDED JUNE 30, 1999
</LEGEND>
<CIK>                                     000815274
<NAME> WINSTON RESOURCES, INC. AND SUBSDIARIES
<MULTIPLIER>                                   1
<CURRENCY>                                     U.S. Dollars

<S>                                             <C>
<PERIOD-TYPE>                                    6-MOS
<FISCAL-YEAR-END>                                DEC-31-1999
<PERIOD-START>                                   JAN-1-1999
<PERIOD-END>                                     JUN-30-1999
<EXCHANGE-RATE>                                  1.000
<CASH>                                           2,617,000
<SECURITIES>                                     477,000
<RECEIVABLES>                                    8,498,000
<ALLOWANCES>                                     200,000
<INVENTORY>                                      0
<CURRENT-ASSETS>                                 12,067,000
<PP&E>                                           1,392,000
<DEPRECIATION>                                   759,000
<TOTAL-ASSETS>                                   13,319,000
<CURRENT-LIABILITIES>                            4,999,000
<BONDS>                                          0
<PREFERRED-MANDATORY>                            0
<PREFERRED>                                      0
<COMMON>                                         32,000
<OTHER-SE>                                       8,051,000
<TOTAL-LIABILITY-AND-EQUITY>                     13,319,000
<SALES>                                          29,773,000
<TOTAL-REVENUES>                                 29,773,000
<CGS>                                            0
<TOTAL-COSTS>                                    23,739,000
<OTHER-EXPENSES>                                 4,592,000
<LOSS-PROVISION>                                 0
<INTEREST-EXPENSE>                               4,000
<INCOME-PRETAX>                                  1,438,000
<INCOME-TAX>                                     661,000
<INCOME-CONTINUING>                              777,000
<DISCONTINUED>                                   0
<EXTRAORDINARY>                                  0
<CHANGES>                                        0
<NET-INCOME>                                     777,000
<EPS-BASIC>                                    .24
<EPS-DILUTED>                                    .23


</TABLE>
Filing Services Provided by RR Donnelley Financial -- Consent of Ernst & Young



[Ernst & Young Letterhead] 
 
EXHIBIT 10.2 
 
 
CONSENT OF INDEPENDENT ACCOUNTANTS 
 
We consent to
the incorporation by reference in the Registration Statement (Form S-8 No. 333-32818) pertaining to the Stock Option Plan of IFCO Systems N.V. of our report dated March 21, 2003 with respect to the consolidated financial statements of IFCO Systems
N.V. included in (Form 20-F) for the year ended December 31, 2002. 
 
March 28, 2003 
 

	 Ernst & Young AG
 Wirtschaftsprüfungsgesellschaft
	 	 	 	 
	
	 By:
	 	 /s/    THOMAS
SPANNAGL        

	 	 	 	 By:
	 	 /s/    ANKE FURCHE
        


	 	 	 (Thomas Spannagl)
 (Wirschaftsprüfer)
	 	 	 	 	 	 (Anke Furche)
 (Wirtschaftsprüferin)
EXHIBIT 32.1
                                                                    ------------


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GVC Venture Corp. (the "Company") on
Form 10-QSB for the quarter ended December 31, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Gordon
Banks, Principal Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 that, to the best of my knowledge:

        (1)    The Report fully complies with the requirements of Section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

        (2)    The information contained in the report fairly presents, in all
               material respects, the financial condition and results of
               operations of the Company.

Date: February 17, 2004

                                                  /s/ Gordon Banks
                                                  ------------------------------
                                                  Gordon Banks
                                                  President (Principal Executive
                                                  Officer) and Director







                                       13
**FIRST	COAST	AERIAL	IMAGING	MISSION	CHECKLIST** Aircraft:		N Date: Location/Mission: Preflight	Planning

o Aircraft/Controller/Battery	Firmware	Up
- to - Date o Weather	Forecast o FAA	/	Local	Rules	Cleared o Permissions	from	local	agencies	and	participating individuals o Obstructions	in	area	noted o Brief	Visual	Observer	of	planned	mission System o Aircraft/Controller/Display	Batteries	charged

o All	cables	in	good	condition o All	propellers	in	good	condition o Airframe	free	of	damage o Gimbal/Camera	attached	properly o Launc h	Location	Checked Post	Start o Controller	Interface	good	with	aircraft

o Satisfactory	GPS satellites received o Battery	Level	Acceptable o Calibrate	Compass o Check	IMU o Check	Flight	Mode o Proper	Home	Point	Established o Check	Propellers	After	Motor	Start o Clear	Launch Area Launch o Hover	10
- 15	feet	above	ground

o Check	for	drift o Check	stick	response o Check	controller	display	for	alerts o Check	Satellite	Integrity Mission o Monitor	Battery	Level

o Monitor	Obstructions	in	Area o Monitor	Aircraft	Response o Note	any	Home	Point	Changes o C lear	Landing	Area After	Landing

o Check	Propeller	Condition o Check	for	Damage	to	Aircraft o Check	for	Systems	Malfunctions o Battery	Number

_____ Flight	Time

__________Battery	Percentage	Remaining

_____ o Battery	Number

_____ Flight	Time

__________Battery Percentage	Remaining

_____ o Battery	Number

_____ Flight	Time

__________Battery	Percentage	Remaining

_____
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1670 Neon gas analyzer. ( a ) *Identification.* A neon gas analyzer is a device intended to measure the concentration of neon in a gas mixture exhaled by a patient. The device may use techniques such as mass spectrometry or thermal conductivity.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2160 Discrete photometric chemistry analyzer for clinical use. ( a ) *Identification.* A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2-wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2309, Jan. 14, 2000]
# C_2014339EN.01002301.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/23 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/23

---

Action brought on 18 July 2014 — GEA Group v OHIM (engineering for a better world)

(Case T-545/14)

2014/C 339/28

Language of the case: German

Parties

Parties

Applicant: GEA Group AG (Düsseldorf, Germany) (represented by J. Schneiders, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 2 June 2014 in Case R 303/2014-4; |
| --- | --- |

—

annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 2 June 2014 in Case R 303/2014-4;

| — | order the Office for Harmonisation in the Internal Market (Trade Marks and Designs) to pay the costs. |
| --- | --- |

—

order the Office for Harmonisation in the Internal Market (Trade Marks and Designs) to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: the word mark ‘engineering for a better world’ for goods and services in Classes 6, 7, 9, 11, 35, 37, 39, 41 and 42 — application for registration of a Community trade mark No 1 2 0 34  807

Community trade mark concerned:

Decision of the Examiner: Rejection of the application for registration

Decision of the Examiner:

Decision of the Board of Appeal: Dismissal of the appeal

Decision of the Board of Appeal:

Plea in law: Infringement of Article 7(1)(b) of Regulation No 207/2009

Plea in law:

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1440 Lactate dehydrogenase test system. ( a ) *Identification.* A lactate dehydrogenase test system is a device intended to measure the activity of the enzyme lactate dehydrogenase in serum. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction, and tumors of the lung or kidneys.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 63 FR 59225, Nov. 3, 1998]
H. R. 7893 

One Hundred Eighteenth Congress 

of the 

United States of America 

AT THE SECOND SESSION 

Begun and held at the City of Washington on Wednesday, 

the third day of January, two thousand and twenty-four 

An Act 

To designate the facility of the United States Postal Service located at 306 Pickens 

Street in Marion, Alabama, as the ‘‘Albert Turner, Sr. Post Office Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. ALBERT TURNER, SR. POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 306 Pickens Street in Marion, Alabama, shall 

be known and designated as the ‘‘Albert Turner, Sr. Post Office 

Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Albert Turner, Sr. Post Office Building’’. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5430 Gas-scavenging apparatus. ( a ) *Identification.* A gas-scavenging apparatus is a device intended to collect excess anesthetic, analgesic, or trace gases or vapors from a patient's breathing system, ventilator, or extracorporeal pump-oxygenator, and to conduct these gases out of the area by means of an exhaust system.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5760 Chemical cold pack snakebite kit. ( a ) *Identification.* A chemical cold pack snakebit kit is a device consisting of a chemical cold pack and tourniquet used for first-aid treatment of snakebites.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any chemical cold pack snakebite kit that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a chemical cold pack snakebite kit that was in commercial distribution before May 28, 1976. Any other chemical cold pack snakebite kit shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[45 FR 69682, Oct. 21, 1980, as amended at 52 FR 17739, May 11, 1987; 61 FR 50708, Sept. 27, 1996]
#### Scaros *v.*Chacker

[No. 17,262.

Filed September 28, 1944.]

*68
      *Frank A. Rondinelli,*of Gary, for appellant.

*George P. Rose,*of Gary, and *E. Miles Norton,*of Crown Point, for appellee.

Royse, J.

— Appellant seeks to prosecute this appeal from an agreed judgment of the Lake Circuit Court in an action there involving a partnership between the parties hereto. After the judgment, which shows on its face that it was made by the court on the agreement of the parties, appellant filed what he denominated a motion for a new trial in which he averred that he had not agreed to the judgment, that it was obtained by fraud, and for the further reasons that the finding and decision of the court is not sustained by sufficient evidence and is contrary to law. After hearing evidence on this motion it was overruled by the trial court.

Appellee has filed his motion to dismiss this appeal. The motion contains several specifications. We deem it necessary to consider only two of these. (1) This is a purported appeal from an agreed judgment; (2) that the purported transcript shows upon its face that appellant’s objections were denied after a three day hearing by the trial court, and the evidence supporting the court’s decision is not made a part of the record herein.

“It is a general rule that an order, judgment, or decree, entered by the court upon the consent of the parties litigant, being in the nature of a contract to which the court has given its formal approval, cannot subsequently be opened, changed, or set aside without the assent of the parties, in the absence of fraud, mutual mistake, or actual absence of consent, and then only by an appropriate legal proceeding.” 139 A. L. R. 422, and authorities cited under Point II. See also, *McMahan*v. *McMahan*(1895), 142*69Ind. 110, 40 N. E. 661; *Shannon*v. *Abshire*(1924), 81 Ind. App. 299, 141 N. E. 621.

The question of the trial court’s ruling on the motion for a new trial requires a consideration of the evidence. No bill of exceptions containing the evidence heard by the trial court on this question has been filed. Therefore, no question has been presented for our consideration.

3. Moreover, in a supplemental motion to dismiss this appeal appellee has filed the certified record of the clerk of the Lake Circuit Court showing that appellant personally received and receipted for the sum of $392, which was part of the benefits granted him in the judgment he here seeks to attack. It is provided by § 2-3201, Burns’ 1933, in part, as follows: “The party obtaining judgment shall not take an appeal after receiving any money paid or collected thereon.” Appellant, having accepted benefits from the judgment herein, cannot now have that judgment reversed. *Beard et al.*v. *Hosier et al.*(1915), 58 Ind. App. 14, 107 N. E. 558; *Wyncoop, Administrator et al.*v. *Laughner et al.*(1939), 106 Ind. App. 457, 19 N. E. (2d) 486.

For the reasons herein set out, the appeal must be dismissed.

Note. — Reported in 56 N. E. (2d) 505.
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3210 Finger joint metal/metal constrained cemented prosthesis. ( a ) *Identification.* A finger joint metal/metal constrained cemented prosthesis is a device intended to be implanted to replace a metacarpophalangeal (finger) joint. This device prevents dislocation in more than one anatomic plane and has components which are linked together. This generic type of device includes prostheses that are made of alloys, such as cobalt-chromium-molybdenum, and is limited to those prostheses intended for use with bone cement (§ 888.3027).
( b ) *Classification.* Class III.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any finger joint metal/metal constrained cemented prosthesis that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a finger joint metal/metal constrained cemented prosthesis that was in commercial distribution before May 28, 1976. Any other finger joint metal/metal constrained cemented prosthesis shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[52 FR 33702, Sept. 4, 1987, as amended at 61 FR 50709, Sept. 27, 1996]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3290 Gonococcal antibody test (GAT). ( a ) *Identification.* A gonococcal antibody test (GAT) is an in vitro device that consists of the reagents intended to identify by immunochemical techniques, such as latex agglutination, indirect fluorescent antibody, or radioimmunoassay, antibodies to *Neisseria gonorrhoeae* in sera of asymptomatic females at low risk of infection. Identification of antibodies with this device may indicate past or present infection of the patient with *Neisseria gonorrhoeae.*
( b ) *Classification.* Class III (premarket approval) (transitional device).
( c ) *Date PMA or notice of completion of a PDP is required.* As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 866.3.
[47 FR 50823, Nov. 9, 1982, as amended at 52 FR 17734, May 11, 1987]
|   | 1. | The      Report fully complies with the requirements of Section 13(a) or 15(d) of      the Securities Exchange Act of      1934; and |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The      information contained in the Report fairly presents, in all material      respects, the financial condition and results      of operation of the Company. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  |  November      16, 2009 |   | By:    | /s/      Edward P. Smolyansky                                                                     |   |
|--------|------------------------------|--------|--------|---------------------------------------------------------------------------------------------------|--------|
|   |                         |   |   | Edward      P. SmolyanskyChief      Financial  and AccountingOfficer      and Treasurer |   |
Exhibit 31.a

I, John P. Manning, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Affordable Housing II Limited Partnership;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



1. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
2. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
3. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and





1. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



1. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
2. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.





|Date: January 23, 2007 | /s/ John P. Manning        
|---------------------- | ---------------------------
|                       | John P. Manning            
|                       | Principal Executive Officer
|                       |                            
|                       |                            
|                       |